{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:09:48Z","timestamp":1789074588780,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032850","name":"EU4Health","doi-asserted-by":"publisher","award":["101102733"],"award-info":[{"award-number":["101102733"]}],"id":[{"id":"10.13039\/100032850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.chom.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:37:33Z","timestamp":1788968253000},"page":"1698-1703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward medical countermeasures against hantaviruses"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-5543","authenticated-orcid":false,"given":"Martin","family":"Ferri\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2026.08.002_bib1","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1473-3099(23)00128-7","article-title":"Hantavirus in humans: a review of clinical aspects and management","volume":"23","author":"Vial","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2026.08.002_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrmicro3066","article-title":"Uncovering the mysteries of hantavirus infections","volume":"11","author":"Vaheri","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.chom.2026.08.002_bib3","series-title":"Global Virology V: 21st Century Vaccines and Viruses","first-page":"781","article-title":"Vaccines Against Hantavirus Disease: Strategies, Outcomes, and Future Directions","author":"Nnamani","year":"2025"},{"key":"10.1016\/j.chom.2026.08.002_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s44298-026-00200-w","article-title":"Vaccines and therapeutics for Andes hantavirus","volume":"4","author":"Tscherne","year":"2026","journal-title":"Npj Viruses"},{"key":"10.1016\/j.chom.2026.08.002_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.chom.2023.05.012","article-title":"Antiviral strategies for epidemic and pandemic preparedness","volume":"31","author":"Jochmans","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2026.08.002_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01600-24","article-title":"Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source","volume":"15","author":"Brocato","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.chom.2026.08.002_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg1855","article-title":"Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody","volume":"15","author":"Mittler","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chom.2026.08.002_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106091","article-title":"Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection","volume":"124","author":"Clark","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.chom.2026.08.002_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023560","article-title":"In Vitro and In Vivo Activity of Ribavirin against Andes Virus Infection","volume":"6","author":"Safronetz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.chom.2026.08.002_bib10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/425007","article-title":"Placebo-Controlled, Double-Blind Trial of Intravenous Ribavirin for the Treatment of Hantavirus Cardiopulmonary Syndrome in North America","volume":"39","author":"Mertz","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chom.2026.08.002_bib11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3389\/fphar.2019.01203","article-title":"An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection","volume":"10","author":"Ye","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.chom.2026.08.002_bib12","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.08.002_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41586-025-09906-y","article-title":"Oral 4\u2032-fluorouridine rescues nonhuman primates from advanced Lassa fever","volume":"650","author":"Cross","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.chom.2026.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2026.106467","article-title":"Potent in vitro antiviral activity of 4\u2019-Fluorouridine against diverse orthohantaviruses including Andes virus","volume":"252","author":"Shrivastava-Ranjan","year":"2026","journal-title":"Antiviral Res"},{"key":"10.1016\/j.chom.2026.08.002_bib15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.cmi.2026.05.047","article-title":"First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib","volume":"32","author":"Est\u00e9banez","year":"2026","journal-title":"Clin. Microbiol. Infection."}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826003227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826003227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:43:46Z","timestamp":1789073026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312826003227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1931312826003227"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2026.08.002","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward medical countermeasures against hantaviruses","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}